CAP-T CAP cells, which are immortalized cell lines, produce transient and stable protein.
The CAP Technology allows for superior protein yields in a shorter time than traditional methods, according to CEVEC.
CEVEC CEO Wolfgang Kintzel said, ”We’re very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules.”
Yuhan Research Institute Bio-Innovation unit head Jong-Gyun Kim said, ”We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."